Literature DB >> 32070224

APOE-ε4 Genotype and Dementia Before and After Transient Ischemic Attack and Stroke: Population-Based Cohort Study.

Sarah T Pendlebury1, Debbie Poole1, Annette Burgess1, Julia Duerden1, Peter M Rothwell1.   

Abstract

Background and Purpose- APOE-ε4 genotype is a risk factor for sporadic Alzheimer disease and reduced recovery from brain injury. Since data on APOE genotype and dementia associated with transient ischemic attack/stroke are sparse, we determined the associations in a longitudinal population-based cohort. Methods- All patients with transient ischemic attack or stroke (2002-2012) in a defined population of 92 728 OxVASC (Oxford Vascular Study) had follow-up to 5-years. Pre-event and incident postevent dementia were ascertained through direct patient assessment and follow-up, supplemented by review of hospital/primary care records. Associations between pre- and post-event dementia and APOE genotype (ε4/ε4-homozygous and ε4/ε3-heterozygous versus ε3/ε3) were examined using logistic regression and Cox regression models, respectively, adjusted for age, sex, education, cerebrovascular burden (stroke severity, prior stroke, white matter disease), diabetes mellitus, and dysphasia. Results- Among 1767 genotyped patients (mean/SD age, 73.0/13.0 years, 901 [51%] male, 602 [34%] transient ischemic attack), 1058 (59.9%) were APOE-ε3/ε3, 403 (22.8%) were ε4/ε3 and 30 (1.7%) were ε4-homozygous. Homozygosity was associated with both pre-event (adjusted odds ratio, 5.81 [95% CI, 1.93-17.48]; P=0.002) and postevent dementia (adjusted hazard ratio, 3.64 [95% CI, 1.90-7.00]; P<0.0001). Association with postevent dementia was maintained after further adjustment for baseline cognitive impairment (hazard ratio, 2.41 [95% CI, 1.19-4.89]; P=0.01). There were no associations overall between ε4/ε3 and pre-event dementia (adjusted odds ratio, 1.47 [95% CI, 0.88-2.45]; P=0.14) or postevent dementia (hazard ratio, 1.11 [95% CI, 0.84-1.48]; P=0.47). Conclusions- In patients with transient ischemic attack and stroke, APOE-ε4 homozygosity was associated with both pre- and post-event dementia. Associations were independent of cerebrovascular burden and may be mediated through increased neurodegenerative pathology or vulnerability to injury.

Entities:  

Keywords:  apolipoprotein E4; brain injuries; cohort studies; dementia; genotype; stroke

Year:  2020        PMID: 32070224      PMCID: PMC7224982          DOI: 10.1161/STROKEAHA.119.026927

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  49 in total

1.  Higher prevalence of cerebral white matter hyperintensities in homozygous APOE-ɛ4 allele carriers aged 45-75: Results from the ALFA study.

Authors:  Santiago Rojas; Anna Brugulat-Serrat; Nuria Bargalló; Carolina Minguillón; Alan Tucholka; Carles Falcon; Andreia Carvalho; Sebastian Morán; Manel Esteller; Nina Gramunt; Karine Fauria; Jordi Camí; José L Molinuevo; Juan D Gispert
Journal:  J Cereb Blood Flow Metab       Date:  2017-05-11       Impact factor: 6.200

Review 2.  Genetic mutations affecting human lipoproteins, their receptors, and their enzymes.

Authors:  V I Zannis; D Kardassis; E E Zanni
Journal:  Adv Hum Genet       Date:  1993

3.  Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation.

Authors:  A J Slooter; M X Tang; C M van Duijn; Y Stern; A Ott; K Bell; M M Breteler; C Van Broeckhoven; T K Tatemichi; B Tycko; A Hofman; R Mayeux
Journal:  JAMA       Date:  1997-03-12       Impact factor: 56.272

4.  APOE epsilon4 and cognitive decline in older stroke patients with early cognitive impairment.

Authors:  C G Ballard; C M Morris; H Rao; J T O'Brien; R Barber; S Stephens; E Rowan; A Gibson; R N Kalaria; R A Kenny
Journal:  Neurology       Date:  2004-10-26       Impact factor: 9.910

5.  Apolipoprotein epsilon 4 homozygosity in young men with coronary heart disease.

Authors:  F M van Bockxmeer; C D Mamotte
Journal:  Lancet       Date:  1992-10-10       Impact factor: 79.321

6.  Joint effect of stroke and APOE 4 on dementia risk: the Canadian Study of Health and Aging.

Authors:  Y P Jin; T Østbye; J W Feightner; S Di Legge; V Hachinski
Journal:  Neurology       Date:  2007-10-31       Impact factor: 9.910

7.  Methodological factors in determining rates of dementia in transient ischemic attack and stroke: (I) impact of baseline selection bias.

Authors:  Sarah T Pendlebury; Ping-Jen Chen; Linda Bull; Louise Silver; Ziyah Mehta; Peter M Rothwell
Journal:  Stroke       Date:  2015-02-05       Impact factor: 7.914

8.  Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study).

Authors:  P M Rothwell; A J Coull; L E Silver; J F Fairhead; M F Giles; C E Lovelock; J N E Redgrave; L M Bull; S J V Welch; F C Cuthbertson; L E Binney; S A Gutnikov; P Anslow; A P Banning; D Mant; Z Mehta
Journal:  Lancet       Date:  2005-11-19       Impact factor: 79.321

9.  Methodological Factors in Determining Risk of Dementia After Transient Ischemic Attack and Stroke: (II) Effect of Attrition on Follow-Up.

Authors:  Sarah T Pendlebury; Ping-Jen Chen; Sarah J V Welch; Fiona C Cuthbertson; Rose M Wharton; Ziyah Mehta; Peter M Rothwell
Journal:  Stroke       Date:  2015-05-07       Impact factor: 7.914

10.  Age- and sex-specific rates of leukoaraiosis in TIA and stroke patients: population-based study.

Authors:  Michela Simoni; Linxin Li; Nicola L M Paul; Basil E Gruter; Ursula G Schulz; Wilhelm Küker; Peter M Rothwell
Journal:  Neurology       Date:  2012-09-05       Impact factor: 9.910

View more
  10 in total

1.  APOE4 Accelerates Development of Dementia After Stroke: Is There a Role for Cerebrovascular Dysfunction?

Authors:  Axel Montagne; Daniel A Nation; Berislav V Zlokovic
Journal:  Stroke       Date:  2020-02-18       Impact factor: 7.914

Review 2.  APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases.

Authors:  Rosalía Fernández-Calle; Sabine C Konings; Javier Frontiñán-Rubio; Juan García-Revilla; Lluís Camprubí-Ferrer; Martina Svensson; Isak Martinson; Antonio Boza-Serrano; José Luís Venero; Henrietta M Nielsen; Gunnar K Gouras; Tomas Deierborg
Journal:  Mol Neurodegener       Date:  2022-09-24       Impact factor: 18.879

Review 3.  Neurovascular Dysfunction in Diverse Communities With Health Disparities-Contributions to Dementia and Alzheimer's Disease.

Authors:  Napatsorn Saiyasit; Evan-Angelo R Butlig; Samantha D Chaney; Miranda K Traylor; Nanako A Hawley; Ryleigh B Randall; Hanna V Bobinger; Carl A Frizell; Franklin Trimm; Errol D Crook; Mike Lin; Benjamin D Hill; Joshua L Keller; Amy R Nelson
Journal:  Front Neurosci       Date:  2022-06-29       Impact factor: 5.152

Review 4.  The Cognitive Sequelae of Transient Ischemic Attacks-Recent Insights and Future Directions.

Authors:  Aravind Ganesh; Philip A Barber
Journal:  J Clin Med       Date:  2022-05-07       Impact factor: 4.964

Review 5.  Cognitive impairment in patients with cerebrovascular disease: A white paper from the links between stroke ESO Dementia Committee.

Authors:  Ana Verdelho; Joanna Wardlaw; Aleksandra Pavlovic; Leonardo Pantoni; Olivier Godefroy; Marco Duering; Andreas Charidimou; Hugues Chabriat; Geert Jan Biessels
Journal:  Eur Stroke J       Date:  2021-02-28

6.  Rates, risks and routes to reduce vascular dementia (R4vad), a UK-wide multicentre prospective observational cohort study of cognition after stroke: Protocol.

Authors:  Joanna M Wardlaw; Fergus Doubal; Rosalind Brown; Ellen Backhouse; Lisa Woodhouse; Philip Bath; Terence J Quinn; Thompson Robinson; Hugh S Markus; Richard McManus; John T O'Brien; David J Werring; Nikola Sprigg; Adrian Parry-Jones; Rhian M Touyz; Steven Williams; Yee-Haur Mah; Hedley Emsley
Journal:  Eur Stroke J       Date:  2020-10-11

Review 7.  Blood-brain barrier disruption in atrial fibrillation: a potential contributor to the increased risk of dementia and worsening of stroke outcomes?

Authors:  Ritambhara Aryal; Adjanie Patabendige
Journal:  Open Biol       Date:  2021-04-21       Impact factor: 6.411

8.  Cholesterol, Atherosclerosis, and APOE in Vascular Contributions to Cognitive Impairment and Dementia (VCID): Potential Mechanisms and Therapy.

Authors:  Michael Tran Duong; Ilya M Nasrallah; David A Wolk; Catherine C Y Chang; Ta-Yuan Chang
Journal:  Front Aging Neurosci       Date:  2021-03-25       Impact factor: 5.750

Review 9.  Common Protective Strategies in Neurodegenerative Disease: Focusing on Risk Factors to Target the Cellular Redox System.

Authors:  Patrizia Hrelia; Giulia Sita; Marina Ziche; Emma Ristori; Angela Marino; Marika Cordaro; Raffaella Molteni; Vittoria Spero; Marco Malaguti; Fabiana Morroni; Silvana Hrelia
Journal:  Oxid Med Cell Longev       Date:  2020-08-01       Impact factor: 6.543

Review 10.  Blood Biomarkers for Detection of Brain Injury in COVID-19 Patients.

Authors:  Steven T DeKosky; Patrick M Kochanek; Alex B Valadka; Robert S B Clark; Sherry H-Y Chou; Alicia K Au; Christopher Horvat; Ruchira M Jha; Rebekah Mannix; Stephen R Wisniewski; Max Wintermark; Susan E Rowell; Robert D Welch; Lawrence Lewis; Stacey House; Rudolph E Tanzi; Darci R Smith; Amy Y Vittor; Nancy D Denslow; Michael D Davis; Olena Y Glushakova; Ronald L Hayes
Journal:  J Neurotrauma       Date:  2020-11-11       Impact factor: 5.269

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.